
Home » EMA Wants to See More Elderly Patients in Anticancer Drug Studies
EMA Wants to See More Elderly Patients in Anticancer Drug Studies
The European Medicines Agency (EMA) has finalized a revised guideline on anticancer drug development, placing additional emphasis on the inclusion of elderly patients in clinical trials. The elderly and frail constitute a vulnerable group of patients rarely included in conventional studies of oncology drugs, for which they are the most likely recipients, the agency said.
Clinical Trials Advisor
Clinical Trials Advisor
Upcoming Events
-
10Aug
-
08Sep
-
15Sep
-
20Sep
-
21Sep
-
22Sep